Trial
NCT04051996
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
Pfizer
Condition
ACUTE MYELOID LEUKEMIA
Intervention
Glasdegib
Why stopped
Unable to accrue patients following COVID-19 study pause.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-15